Calmark receives follow-up order from Greece

Calmark announced today that the company received a follow-up order from Greece regarding the Neo-Bilirubin test cassettes. Today's order is of less economic value.

Calmark receives the first recurring order from Greece for test cassettes, which shows that the clinics in Greece that previously purchased Calmark POC instruments and test cassettes for measuring bilirubin are using the products in daily consumption.

"This order shows that a quick point-of-care response to bilirubin makes it easier for healthcare and that our products are used and needed," comments Calmark's CEO Anna Söderlund. "We look forward to continued cooperation with our distributor in Greece."

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.